Abstract 19P
Background
County-level hospitals, as the "gatekeepers" for rural cancer patients (pts) in the hierarchical diagnosis and treatment system (HDTS) in China, shoulder significant responsibilities in facilitating cancer treatment and patient referrals. Here, we report the referral data from the CHASE001 trial (NCT05544123).
Methods
CHASE001, a prospective, non-interventional multicenter study exploring real-world treatment and referral practices among pts in Chinese county-level hospitals with HER2+ or HR+/HER2- breast cancer (BC) is ongoing since Sep. 2022. The primary endpoint is to describe the treatment patterns. A key secondary endpoint is referral behavior. Descriptive statistics were utilized to analyze the referral data.
Results
At data cutoff (May 17, 2023), 1436 BC pts were included from 26 county-level hospitals in China. 1172 (81.62%) pts were initially diagnosed at county-level hospitals, among them, 81 (6.91%) pts were subsequently referred to higher-level hospitals. 58 out of 81 pts were referred out primarily to receive breast surgery (71.60%), and most of them were eventually referred back to county-level hospitals to receive adjuvant systemic treatment (94.83%, 55/58). Among 264 pts who were initially diagnosed at higher-level hospitals, a significant portion (84.09%) were referred to county-level hospitals to receive adjuvant systemic treatment. The majority (75.99%, 1092/1436) underwent the entire process of diagnosis and treatment within the county-level hospitals without requiring referral-out, however. Among 341 pts who received treatment at higher-level hospitals, 153 (44.87%) brought back their treatment plan to county-level hospitals, and the majority (90.20%, 138/153) adhered to that treatment plan. Interestingly, pts with higher education levels, and employee medical insurance were more inclined to seek treatment at higher-level hospitals, primarily to recieve breast surgery and neoadjuvant treatment.
Conclusions
Most of the patients admitted to county-level hospitals in China underwent the entire process of diagnosis and treatment within these hospitals, indicated that further efforts to provide high quality, guideline centric care should be concentrated at county-level hospitals.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract